KRAS has long been considered an undruggable target (12), and most patients with advanced KRAS-mutant NSCLC currently receive conventional platinum-based chemotherapy, which is associated with poor prognosis. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.